Carigent: The tail is the tale

The dual challenge of liposomal-based delivery of biologics has been to increase time in circulation and reach target organs before the delivery device degrades or prematurely releases its payload. Carigent Therapeutics Inc. believes its ability to non-covalently integrate target ligands into a polylactic-co-glycolic acid delivery vehicle will solve those challenges and give it an advantage over other nanoparticle systems that rely on covalently attached ligands.

The PLGA polymer matrix is used in many FDA-approved biodegradable devices such as sutures and grafts. The time to degradation can be modified by varying the ratio of lactide to glycolide in the polymer...